{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Complete Remission with platelet recovery"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Remission w/incomplete platelet recovery"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Partial remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Progressive disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Best Response in Ph+ ALL patients was defined as either Complete Remission (CR) with platelet recovery, Complete Remission (CR) with incomplete platelet recovery, Partial Remission (PR) or Stable disease. Stable disease was defined is defined as failure to qualify for either CR, PR, or progressive disease.","groups":[{"description":"1 year to \\< 10 years pediatric patients","id":"OG000","title":"Group 1"},{"description":"\\>= 10 years to \\<18 years pediatric patients","id":"OG001","title":"Group 2"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.","reportingStatus":"POSTED","timeFrame":"minimum of 12 cycles (28 days per cycle)","title":"Efficacy Endpoints for Ph+ ALL Patients","type":"SECONDARY","unitOfMeasure":"Participants"}